Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 11:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lialda Clear all
Terminated Phase 3 Interventional Results available

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis

NCT01004185
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Asacol 400 mg
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
5 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 24, 2012 · Synced Sep 7, 2026, 11:10 PM EDT
Terminated Phase 3 Interventional Results available

A Study With Pentasa in Patients With Active Crohn's Disease

NCT00862121
View directory record Official record
Conditions
Crohn´s Disease
Interventions
Pentasa, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
7
States / cities
San Diego, California • Clearwater, Florida • John's Creek, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Phase 2Phase 3 Interventional

Trial of Mesalamine for the Treatment of Active Microscopic Colitis

NCT00952952
View directory record Official record
Conditions
Microscopic Colitis, Diarrhea
Interventions
Mesalamine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 23, 2011 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

NCT03283085
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis
Interventions
25 mg Ontamalimab, 75 mg Ontamalimab
Drug
Lead sponsor
Shire
Industry
Eligibility
16 Years to 80 Years
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
103
States / cities
Mesa, Arizona • Phoenix, Arizona • Sun City, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Phase 4 Interventional Results available

Dose Escalation and Remission (DEAR)

NCT00652145
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
mesalamine
Drug
Lead sponsor
James Lewis
Other
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
8
States / cities
Naples, Florida • Winter Park, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis

NCT02093663
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
MMX Mesalamine/Mesalazine (Low Dose), MMX Mesalamine/Mesalazine (High Dose)
Drug
Lead sponsor
Shire
Industry
Eligibility
5 Years to 17 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
9
States / cities
Baltimore, Maryland • Boston, Massachusetts • Newton, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects

NCT03327558
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Apriso 0.375G ER CAP, APRISO 375 mg extended-release capsules
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 7, 2026, 11:10 PM EDT
Completed No phase listed Observational

Adherence to Mesalamine Profile for Patients With Inflammatory Bowel Disease

NCT01349504
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2013 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Phase 3 Interventional

Mesalamine Pellet to Maintain Remission of Mild to Moderate Ulcerative Colitis

NCT00767728
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Granulated mesalamine, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Mexico, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis

NCT00073021
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Asacol 800 mg (mesalamine), Asacol 400 mg (mesalamine)
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 75 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
54
States / cities
Scottsdale, Arizona • Anaheim, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2015 · Synced Sep 7, 2026, 11:10 PM EDT
Terminated Phase 4 Interventional Results available

Cimzia Versus Mesalamine for Crohn's Recurrence

NCT01696942
View directory record Official record
Conditions
Crohn's Disease
Interventions
Cimzia, Mesalamine
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2018 · Synced Sep 7, 2026, 11:10 PM EDT
Completed No phase listed Observational

Mesalamine and Reproductive Health Study

NCT01331551
View directory record Official record
Conditions
Colitis Ulcerative, Crohn Disease
Interventions
Not listed
Lead sponsor
Harvard School of Public Health (HSPH)
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)

NCT02522767
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalamine, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
18
States / cities
Little Rock, Arkansas • Murrieta, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2021 · Synced Sep 7, 2026, 11:10 PM EDT
Not listed Phase 2 Interventional

Study of the Safety and Efficacy of Zoenasa® Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis

NCT01586533
View directory record Official record
Conditions
Ulcerative Colitis, Left-sided Ulcerative Colitis, Distal Ulcerative Colitis
Interventions
Zoenasa-1:4, Mesalamine Enema
Drug
Lead sponsor
Altheus Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
45
States / cities
Birmingham, Alabama • Dothan, Alabama • Lakewood, Colorado + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2014 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Phase 4 Interventional Results available

Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis

NCT01124149
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
MMX mesalamine/ mesalazine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
34
States / cities
Birmingham, Alabama • Anaheim, California • Garden Grove, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

A Comparison of Once a Day Dose Compared to 2 Doses/Day

NCT00505778
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalamine Once-Daily, Mesalamine Twice-Daily
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years and older
Enrollment
1,027 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
233
States / cities
Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 205 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2013 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Phase 3 Interventional Results available

Prevention of Recurrence of Diverticulitis

NCT00545740
View directory record Official record
Conditions
Diverticulitis
Interventions
SPD476 (1.2g), SPD476 (2.4 g), SPD476 (4.8 g), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
590 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
46
States / cities
Litchfield Park, Arizona • Little Rock, Arkansas • Anaheim, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2021 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available

Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)

NCT01327300
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Mesalamine, Placebo
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Sep 7, 2026, 11:10 PM EDT
Recruiting Phase 2 Interventional

Confirmatory Clinical Study in Active Ulcerative Colitis

NCT07296315
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Low-dose MH002, High-dose MH002, Placebo
Drug
Lead sponsor
MRM Health NV
Industry
Eligibility
16 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Miami, Florida • Orlando, Florida • Palmetto Bay, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 7, 2026, 11:10 PM EDT
Terminated Phase 3 Interventional

A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)

NCT02849951
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
LT-02, LT-02 Placebo
Drug
Lead sponsor
Prometheus Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
45
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Chula Vista, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Not applicable Interventional Results available

Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma

NCT01577966
View directory record Official record
Conditions
Brain Tumor
Interventions
Sulfasalazine
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Sep 7, 2026, 11:10 PM EDT
Terminated Phase 4 Interventional Results available

Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib

NCT03591770
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
SHINGRIX
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Phase 2 Interventional Results available

Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea

NCT01177410
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Placebo, Mesalamine Granules 750 mg, Mesalamine Granules 1500 mg
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Sherwood, Arkansas • Anaheim, California • Sacramento, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 7, 2026, 11:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sulfamethoxazole Drug Interaction Study With MMX® Mesalazine/Mesalamine

NCT01469637
View directory record Official record
Conditions
Healthy
Interventions
sulfamethoxazole + MMX placebo, Sulfamethoxazole + MMX Mesalazine/mesalamine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2021 · Synced Sep 7, 2026, 11:10 PM EDT